In patients aged 65 and older, which pneumococcal vaccine is recommended?

In patients aged 65 and older, the recommendation for pneumococcal vaccination involves the use of both Prevnar 13 and Pneumovax (23); however, specifically for the context of the question, Pneumovax 23 is highlighted as essential. Pneumovax 23 is a polysaccharide vaccine that provides protection against 23 serotypes of Streptococcus pneumoniae, which are responsible for a significant number of pneumococcal infections in older adults.

While Prevnar 13, a conjugate vaccine that covers 13 serotypes, is also part of the pneumococcal vaccination strategy, Pneumovax 23 is often the focus for older adults due to its broad coverage and the fact that it is recommended to be given after Prevnar 13 to enhance immunity.

Vaccination against pneumococcal disease in older adults is crucial because this age group is at an increased risk for severe infections, including pneumonia, bacteremia, and meningitis caused by Streptococcus pneumoniae. A comprehensive vaccination approach that includes these vaccines reduces the risk of serious complications related to pneumococcal infections in this vulnerable population.